Orwoll Eric S, Lapidus Jodi, Wang Patty Y, Vandenput Liesbeth, Hoffman Andrew, Fink Howard A, Laughlin Gail A, Nethander Maria, Ljunggren Östen, Kindmark Andreas, Lorentzon Mattias, Karlsson Magnus K, Mellström Dan, Kwok Anthony, Khosla Sundeep, Kwok Timothy, Ohlsson Claes
Division of Endocrinology, Diabetes, and Clinical Nutrition, Bone and Mineral Unit, School of Medicine, Oregon Health & Science University, Portland, OR, USA.
Department of Public Health and Preventive Medicine, Division of Biostatistics, Oregon Health & Science University, Portland, OR, USA.
J Bone Miner Res. 2017 Mar;32(3):633-640. doi: 10.1002/jbmr.3021. Epub 2016 Nov 14.
Measurement of serum testosterone (T) levels is recommended in the evaluation of osteoporosis in older men and estradiol (E2) and sex hormone binding globulin (SHBG) levels are associated with the rate of bone loss and fractures, but the clinical utility of sex steroid and SHBG measurements for the evaluation of osteoporosis in men has not been examined. To evaluate whether measurements of T, E2, and/or SHBG are useful for the prediction of fracture risk or the rate of bone loss in older men, we analyzed longitudinal data from 5487 community-based men participating in the Osteoporotic Fractures in Men (MrOS) study in the United States, Sweden, and Hong Kong. Serum T, E2, and SHBG levels were assessed at baseline; incident fractures were self-reported at 4-month intervals with radiographic verification (US), or ascertained via national health records (Sweden, Hong Kong). Rate of bone loss was assessed by serial measures of hip bone mineral density (BMD). We used receiver operating characteristic (ROC) curves, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) to assess improvement in prediction. Mean age at baseline was 72 to 75 years and the prevalence of low T levels (<300 ng/dL) was 7.6% to 21.3% in the three cohorts. There were 619 incident major osteoporotic and 266 hip fractures during follow-up of approximately 10 years. Based on ROC curves, there were no improvements in fracture risk discrimination for any biochemical measure when added to models, including the Fracture Risk Assessment Tool (FRAX) with BMD. Although minor improvements in NRI were observed for the dichotomous parameters low bioavailable E2 (BioE2) (<11.4 pg/mL) and high SHBG (>59.1 nM), neither sex steroids nor SHBG provided clinically useful improvement in fracture risk discrimination. Similarly, they did not contribute to the prediction of BMD change. In conclusion, there is limited clinical utility of serum E2, T, and SHBG measures for the evaluation of osteoporosis risk in elderly men. © 2016 American Society for Bone and Mineral Research.
建议在评估老年男性骨质疏松症时测量血清睾酮(T)水平,雌二醇(E2)和性激素结合球蛋白(SHBG)水平与骨质流失率和骨折相关,但性激素和SHBG测量对男性骨质疏松症评估的临床实用性尚未得到检验。为了评估T、E2和/或SHBG测量对于预测老年男性骨折风险或骨质流失率是否有用,我们分析了来自美国、瑞典和中国香港参加男性骨质疏松性骨折(MrOS)研究的5487名社区男性的纵向数据。在基线时评估血清T、E2和SHBG水平;通过自我报告每4个月一次并经影像学验证(美国)或通过国家健康记录(瑞典、中国香港)确定新发骨折情况。通过连续测量髋部骨密度(BMD)评估骨质流失率。我们使用受试者工作特征(ROC)曲线、净重新分类改善(NRI)和综合判别改善(IDI)来评估预测的改善情况。基线时的平均年龄为72至75岁,三个队列中低T水平(<300 ng/dL)的患病率为7.6%至21.3%。在大约10年的随访期间有619例新发严重骨质疏松性骨折和266例髋部骨折。根据ROC曲线,当添加到模型中时,包括结合BMD的骨折风险评估工具(FRAX),任何生化指标在骨折风险判别方面均无改善。尽管对于二分参数低生物利用度E2(BioE2)(<11.4 pg/mL)和高SHBG(>59.1 nM)观察到NRI有微小改善,但性激素和SHBG在骨折风险判别方面均未提供临床上有用的改善。同样,它们对BMD变化的预测也没有贡献。总之,血清E2、T和SHBG测量在评估老年男性骨质疏松症风险方面的临床实用性有限。© 2016美国骨与矿物质研究学会。